As a solution, Sheng et al.147 suggested that in ICI treatments, simultaneous inhibition of LSD1 and TGF-β could contribute to the complete eradication of ICI-refractory tumors and prevent tumor recurrence. The gene discussed is KDM1A; the disease is neoplasm.